Reactions appeared near injection site at a median onset of day 8 after first dose; six of 12 patients had no recurrence after second dose
Water exposure, person-to-person contact, contaminated food accounted for more than half of outbreaks in 2012 to 2017
Estimated change in mean body weight to week 68 was −9.6 percent with semaglutide 2.4 mg versus −3.4 percent with placebo
7 percent increase found in psychiatric care volume overall, but 42 percent decrease seen for new patients
Decreases seen in intravitreal injections, lasers and cryotherapy, retinal detachment repairs, other vitrectomies
Adding machine learning-based image analysis allows noninvasive differentiation of benign and premalignant polyps
Comorbidities, including kidney dysfunction, lung disease, and psychiatric illness, tied to higher readmission
A decade after delivery, changes seen in left ventricular structure and function
No significant improvement seen in median time to resolution of symptoms with ivermectin versus placebo
Newly diagnosed pediatric cancer cases decreased in 43 percent of centers; treatment abandonment increased in 34 percent